PARTNERSHIP TO ADVANCE NATION'S CLINICAL RESEARCH CAPABILITIES

broken image

L-R: CRM’s CEO Dr Akhmal Yusof, Health Minister Datuk Seri Dr Dzulkefly Ahmad, Director General of Health Datuk Dr Radzi Abu Hassan & PhAMA President Ms Kam Ai Teng

PUTRAJAYA, Jan 8 (Bernama) -- Clinical Research Malaysia (CRM) and the Pharmaceutical Association of Malaysia (PhAMA) have entered a strategic partnership to propel the development of clinical research talents and skills in Malaysia. The MoU was formalized earlier today during CRM’s Clinical Research Excellence in Early Phase and People Development event in Ministry of Health office.
 
The MOU was signed by Dr Akhmal Yusof, Chief Executive Officer of CRM, and Ms Kam Ai Teng, President of PhAMA and was witnessed by the Minister of Health, Datuk Seri Dr Dzulkefly Ahmad. Under the MoU, PhAMA will support CRM through the provision of proteges on an annual basis for the next three years, effective this year.
 
The partnership will be driven through the CRM’s Centre of Excellence (CoE), which aims to enhance the nation's clinical research capabilities in building skilled study coordinators profession. This initiative will pave the way for fresh graduates to begin their career in clinical research, aligning with the Pharmaceutical Sector's Research and Development (R&D) objectives outlined in the New Industrial Master Plan (NIMP) 2030.
 
“The establishment of the CRM’s Centre of Excellence further solidifies the organizations' dedication to shaping the future of clinical research in Malaysia. Through collaborative efforts, CRM and PhAMA are poised to contribute significantly to the advancement of healthcare and the pharmaceutical sector in the country,” said Datuk Seri Dr Dzulkefly during his speech.
 
Ms. Kam Ai Teng, President of PhAMA, echoed this sentiment, highlighting the crucial role of innovation and research in the pharmaceutical industry. “PhAMA is enthusiastic about contributing to the clinical research landscape in Malaysia. The fact that the top five sponsors of new sponsored research in the last five years are all PhAMA members attests to our steadfast commitment to advancing healthcare through research and development,” Ms. Kam added.

About Pharmaceutical Association of Malaysia (PhAMA)
Pharmaceutical Association of Malaysia (PhAMA) is a non-governmental organisation and premier trade association established in 1972 to facilitate the activities of members consisting of innovative pharmaceuticals and biopharmaceutical multinational companies in Malaysia. Currently, the organization has 40 members who share the mission of driving healthcare reforms towards increased access to innovative medicines in Malaysia. Our members are possess widespread experience and networks with global markets and healthcare systems, including the management of Public Health Emergencies of International Concern (PHEIC) such as the COVID-19 pandemic. PhAMA members invest significantly in Malaysia’s economy in the form of foreign direct investments (FDI), clinical trials, Continuous Medical Education for healthcare professionals and regulatory officers, and employment of over 12,000 workers in STEM positions, moving Malaysia towards a knowledge-based economy.

For information about Clinical Research Malaysia (CRM), please visit:
https://clinicalresearch.my/about-us-2/
 
SOURCE : Clinical Research Malaysia (CRM)

FOR MORE INFORMATION, PLEASE CONTACT:
Name: Siti Khadijah Sakaria
Tel: +6017- 696 3596 | +603-7931 5566 (ext. 119)  
Email: sitikhadijah@clinicalresearch.my  

--BERNAMA